Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 11/20 | 0.55 |
| ▸ | FEN1 | P39748 | 11/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180470 | 0.90 | ALOX5AP (0.47) | ALOX5APFEN1PTGS2PTGS1CA9 | |
| Orthocresol SCHEMBL16180579 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1PTGS2CA1CA2 | |
| 2-Chlorophenol SCHEMBL16180513 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1PTGS2PTGS1CA1 | |
| SCHEMBL16180634 | 0.87 | ALOX5AP (0.47) | ALOX5APFEN1 | |
| Guaiacol SCHEMBL16180776 | 0.86 | ALOX5AP (0.44) | ALOX5APFEN1PTGS2PTGS1CA1 | |
| SCHEMBL16180585 | 0.85 | ALOX5AP (0.43) | ALOX5APFEN1CA2CA9CA12 | |
| SCHEMBL16180522 | 0.85 | ALOX5AP (0.43) | ALOX5APFEN1PTGS2CA9 | |
| SCHEMBL31234503 | 0.83 | ALOX5AP (0.43) | ALOX5APFEN1PTGS2PTGS1CA2 | |
| SCHEMBL16177988 | 0.81 | PTGS2 (0.50) | ALOX5APFEN1PTGS2CA1CA2 | |
| SCHEMBL6883474 | 0.80 | KIF11 (0.50) | ALOX5APFEN1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716529-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2024243343-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | KARANICOLAS JOHN (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20140315878-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | ALOX5AP 1186/4885FEN1 4863/4885PTGS2 209/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALOX5AP 1186/4885FEN1 4863/4885PTGS2 209/4885 |
| US-20150259327-A1 | Chemical Compounds | SULT2A1, SULT1A1, SULT1E1 | ALOX5AP 4059/4885FEN1 4600/4885PTGS2 3678/4885 |
| US-20140315878-A1 | CHEMICAL COMPOUNDS | SULT2A1, SULT1A1, SULT1E1 | ALOX5AP 4059/4885FEN1 4600/4885PTGS2 3678/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALOX5AP 1186/4885FEN1 4863/4885PTGS2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.